Operation TrialBlazer: HHS Bets on Speed to Keep Early-Stage Innovation (and Its IP) at Home
For years, the competitive narrative in pharmaceutical innovation has been framed around the finish line: who reaches marketing approval, who wins the patent litigation, who secures exclusivity. Operation TrialBlazer, the 2026 roadmap from the Department of Health and Human Services (HHS) to maintain U.S. leadership in early clinical research and development, reframes the contest around the starting line. Its thesis is blunt: the United States is losing the race to get molecules into humans, and the investment, intellectual property (IP), and clinical track records that follow first-in-human data are increasingly being built somewhere else.
For patent attorneys, regulatory counsel, and in-house IP teams managing global portfolios, this is more than a domestic policy document. It is a signal about where first-in-human data, one of the most valuable early assets a life-sciences company owns, will be generated, and therefore where IP and regulatory strategy will increasingly need to begin.
The competitive anxiety driving the roadmap
The roadmap opens with a candid acknowledgment that U.S. leadership in early-stage biomedical R&D is no longer guaranteed. A few data points anchor the argument, and they are worth keeping in front of any global filing strategy:
• In 2021, China’s global share of Phase 1 trials surpassed the United States’ share for the first time.
• By 2024, China had surpassed the U.S. in total registered clinical trials, with more than 7,100 registrations - roughly 39% of the global total.
• In 2025, global companies spent over $137 billion licensing China-based assets, meaning American innovation dollars are increasingly financing IP, first-in-human data, and clinical records generated outside the U.S.
• One projection cited in the roadmap holds that drugs developed by Chinese biotech companies could account for 35% of FDA approvals by 2040.
Australia features as the other competitive benchmark. Its Clinical Trial Notification system can have a trial underway in fewer than 70 days after final protocol submission, with regulatory approval in as little as 21 to 28 days and site activation within 6 to 12 weeks. China, following reforms in 2015 and again in September 2025, has compressed its early discovery-to-IND cycle to a pace the roadmap describes as 50% to 70% faster than the rest of the world, and now requires IND applicants to commit to initiating their trial within 12 weeks of submission.
The contrast with the U.S. is more nuanced than the headline might suggest. U.S. IND applications generally go into effect 30 days after FDA receives them, a clock the roadmap describes as comparable to China and Australia. The concern is that the work around that clock is slower: the gap between a pre-IND meeting request and IND submission averages around 380 days, sponsors may wait up to 60 days simply to secure a pre-IND meeting, and post-IND hurdles - Institutional Review Board (IRB) approval, site contracting, and enrollment - can add up to 13 months before a single patient is enrolled. The framing the document returns to repeatedly: the U.S. pathway is measured in years; competitor pathways are measured in months.
Why this matters for IP strategy specifically
The roadmap’s most important insight for IP professionals is one it states almost in passing: first-in-human data is an IP and investment magnet. The country where early clinical data is generated tends to capture the downstream value - the patents, the follow-on investment, the licensing deals, and the clinical “track record” that de-risks later financing. That has several concrete implications:
Where you run first-in-human increasingly shapes where value accrues. If a sponsor is driven offshore for speed, the resulting human data, manufacturing know-how, and trade-secret-protected process knowledge are developed first under another jurisdiction’s regulatory and IP regime. For portfolio strategy, the practical question becomes whether patent filing, publication control, collaboration agreements, and data-exclusivity planning are aligned with where trials actually start, not just where the sponsor eventually intends to market.
Speed-to-clinic interacts with patent term economics. Patent term is a fixed, depleting asset, subject to limited statutory adjustments and extensions. All else equal, every month shaved off the path to first-in-human is a month that can improve the effective commercial window. A development pathway that is two to three years faster can materially change the value of the same patent estate. TrialBlazer is, in this sense, a patent-term-preservation policy dressed as a clinical-operations reform.
Platform and “prior knowledge” reuse has a dual edge. The FDA’s stated plan to expand reliance on prior knowledge - letting sponsors reuse standardized manufacturing and delivery data from one product to support the next, with specific draft guidance for cell and gene therapies - is operationally attractive. But it raises familiar questions for IP counsel: what is the trade-secret posture of platform data being reused across programs, who owns reusable CMC packages in collaborations and CRO relationships, and how does shared prior knowledge interact with enablement and written-description support across a platform’s patent family?
The FDA program: a tour for regulatory counsel
The FDA component is the most detailed part of the roadmap, organized around two priorities: accelerating time to first-in-human trials, and accelerating later-stage development while reducing administrative burden.
Clarifying IND requirements
The central diagnosis is regulatory ambiguity. Because the FDA has not historically spelled out phase-specific data expectations with sufficient clarity, some sponsors over-submit defensively, generating months of unnecessary studies before a therapy can enter humans. The roadmap targets this problem on three fronts.
CMC
The FDA is clarifying what Chemistry, Manufacturing, and Controls (CMC) data is genuinely needed before a Phase 1 trial, pushing back on practices like submitting more than six months of stability data or full commercial-process and exhaustive impurity profiling at a stage where the commercial process does not yet exist. The agency estimates that focusing on risk-based, phase-appropriate requirements could save sponsors 6 to 12 months.
For advanced therapies, including rare-disease cell and gene therapies, the roadmap also emphasizes greater use of “prior knowledge” from standardized and well-understood manufacturing and delivery methods. That could reduce duplicative manufacturing, testing, and safety work across related products, but it also makes platform-data ownership, trade-secret controls, and collaboration agreements more important earlier in development.
Pharmacology and toxicology
The FDA is moving toward a risk-based nonclinical model that weighs population risk (for example, healthy volunteers versus patients with severely debilitating or life-threatening diseases) and pharmaceutical risk (for example, a novel target or modality versus a well-understood target or modality). The agency is also exploring a “weight of evidence” approach, leveraging available nonclinical and clinical data to make a knowledge-based safety evaluation.
A risk-based approach to nonclinical safety studies, use of weight-of-evidence assessments, and incorporation of New Approach Methodologies (NAMs) are expected to produce greater efficiencies and, where scientifically appropriate, reduce animal testing. The roadmap points to draft guidances on streamlined nonclinical safety studies for monoclonal antibodies (December 2025), general considerations for NAMs in drug development (March 2026), and streamlined nonclinical safety studies for oncology biologics and conjugated products (May 2026), as well as a public inventory of contexts in which CDER is open to streamlined nonclinical programs. For sponsors of well-characterized modalities, single-species toxicology or NAM-based packages may become defensible where two-species studies were once reflexive.
Protocol amendments
The protocol-amendment reforms address two related problems: building enough flexibility into the initial protocol to reduce avoidable amendments, and making necessary amendments less opaque once a Phase 1 IND has been submitted. Citing HHS findings that 45% of protocol amendments were somewhat or completely avoidable, and that simplifying protocols and reducing amendments could lower the estimated cost of bringing a drug to market by up to 22%, the FDA plans to refine best practices for dose selection and escalation strategies and offer advice on how sponsors can structure initial clinical protocols to reduce amendment burden.
The FDA also recognizes that amendments are sometimes necessary and can become a source of uncertainty, even when sponsors are not required to wait for formal FDA feedback before proceeding. To address that uncertainty, the roadmap describes a real-time status tracker that would allow sponsors to see when an amendment has been reviewed and when FDA has determined that no action is indicated.
The Expedited-IND Acceleration Pilot
The headline structural reform is a pilot that creates a network of Qualified Research Institutions (QRIs) - academic medical centers, healthcare networks, CROs, and regulatory advisors, that partner with sponsors to develop and pre-review the pharmacology/toxicology, clinical, and CMC components of an IND. Paired with a new real-time rolling submission platform, the model would let the FDA review QRI recommendations and IND components on a rolling basis and communicate securely with the sponsor to provide timely guidance. Like rolling NDA/BLA review under existing expedited programs, this model would allow individual IND components to be reviewed before formal IND submission.
Sponsors retain full ownership of the IND, and FDA retains full regulatory and decision-making authority. For sponsors without deep in-house regulatory teams, the pilot could meaningfully de-risk and accelerate the pre-IND phase. The roadmap also contemplates using the pilot to explore post-IND bottlenecks, including IRB approval, site contracting, and patient enrollment.
IRB reform and trial access
The FDA is considering rulemaking to require a single IRB (sIRB) model for multi-site cooperative studies. Under this approach, one IRB would serve as the “IRB of record” for all participating sites, streamlining review while maintaining oversight. The change would align FDA regulations with the Common Rule and NIH policy, which already require sIRB review for many federally funded studies, and would reduce duplicative site-by-site review that inflates start-up timelines.
Regarding trial access, the roadmap notes that enrollment is consistently one of the most significant bottlenecks in clinical development, with the consequences most often falling on patients. It catalogs structural disincentives on both sides of the enrollment equation: clinician time, workflow disruption, lack of reimbursement, complex eligibility criteria, and limited point-of-care tools on one side; co-pays, travel burdens, unexpected tax liability on compensation, and potential jeopardy to Medicaid eligibility on the other. FDA recognizes that it cannot solve these problems alone and will need sustained collaboration with the Centers for Medicare & Medicaid Services (CMS), the Office of Inspector General (OIG), the Office for Human Research Protections (OHRP), NIH, private insurers, and other stakeholders. It also plans to continue advancing guidance on integrating randomized controlled trials into routine clinical care, reducing the need for patients to seek out specialized trial sites.
Enhanced regulatory guidance to drive efficiency
TrialBlazer also points to FDA guidance outside the pre-IND context that could make later-stage development more efficient. The roadmap highlights a revised draft guidance on demonstrating substantial evidence of effectiveness, clarifying how certain programs may rely on one adequate and well-controlled clinical investigation plus confirmatory evidence to support approval. It also highlights revised draft guidance on master protocols for drug and biological product development, which can allow multiple therapies, patient populations, or sub-studies to be evaluated under a single overarching framework. For platform companies, these guidances are worth reading together with the prior-knowledge and protocol-flexibility reforms: the common theme is reuse of validated scientific, operational, and evidentiary infrastructure rather than rebuilding the same machinery program by program.
Practical resources and engagement
The roadmap recognizes that navigating early clinical development is complex and that the burden is felt disproportionately by smaller companies. Several initiatives are designed to make FDA’s expectations and resources more visible, accessible, and actionable:
• A dedicated Phase 1 First-In-Human IND landing page. FDA plans a centralized digital hub that outlines phase-appropriate requirements, links to relevant guidance documents, provides practical data examples, and answers common sponsor questions.
• A live Phase 1 contact center.FDA has launched a contact center staffed by experts who can answer general questions in real time or connect sponsors with the relevant review division for disease- or product-specific issues. It is not a substitute for product-specific pre-IND interactions, but it can help resolve threshold issues and reduce uncertainty. The Phase 1 support line is 240-276-9358, and the email address is Phase1Questions@fda.hhs.gov.
• Public roundtables and a feedback docket. HHS plans roundtables and a public docket to gather input on streamlining the IND process and clinical trial initiation, improving contracting and IRB reform, accelerating Phase 1 studies, and reducing regulatory uncertainty around participant and sponsor payment.
NIH, ARPA-H, and ONC: the supporting cast
TrialBlazer is FDA-heavy, but it is not FDA-only. The National Institutes of Health (NIH), the Advanced Research Projects Agency for Health (ARPA-H), and the Office of the National Coordinator for Health Information Technology (ONC) supply the infrastructure layer: metrics, networks, data standards, computational tools, and trial-access reforms that FDA cannot deliver by itself.
NIH: operational rigor, reusable infrastructure, and broader reach
NIH’s role is to make the U.S. clinical research enterprise faster without making it looser. The roadmap identifies five NIH workstreams that, if implemented well, could make NIH-funded and NIH-connected trials more predictable, rigorous, and representative.
Ascertain and promulgate key metrics for overseeing clinical research studies
NIH’s first project is deceptively important: define what trial success means before a study is funded, activated, or allowed to drift. The roadmap recognizes that success metrics may vary by program. Given the wide variability among clinical trials and the health-related biomedical outcomes being assessed, there is a need to determine which metrics are indicators of clinical trial progress and what is indicative of trial success. NIH plans to issue a request for information (RIF) to gather data on ways to improve trial start-up efficiency and ongoing performance, enable earlier intervention when trials fall behind, and support go/no-go decisions that direct public funding toward studies most likely to produce meaningful health gains.
For sponsors and institutions, the practical implication is more explicit performance management. For IP and regulatory teams, better trial metrics can also affect disclosure strategy, continuation timing, licensing milestones, and diligence: the earlier the team knows whether a study is likely to produce decision-quality data, the earlier it can decide whether to file, continue, publish, partner, or pivot.
Leverage efficiencies of NIH-supported clinical trial networks
NIH-supported networks, including NCI-Designated Cancer Centers and Clinical and Translational Science Awards (CTSA) hubs, are not just places to run trials. TrialBlazer frames them as testbeds for better trial mechanics. NIH intends to use these networks to improve trial design, activation, recruitment, retention, contracting, regulatory readiness, and oversight, including through reusable clinical and regulatory “playbooks” that capture the scientific, manufacturing, regulatory, and operational steps needed to move programs forward without starting from scratch each time.
The roadmap also emphasizes expanding use of SMART IRB, a national platform and reliance agreement designed to streamline IRB review for multi-site studies. For highly individualized or rare-disease programs, NIH-supported networks may also help design studies that can move efficiently from n-of-1 or individualized approaches to larger Phase 1/2 studies. Finally, the networks can support broader use of NAMs, including human cell-based and computational models, to generate stronger preclinical evidence and improve decisions about which therapeutics are ready for human testing. For practitioners, the message is straightforward: standardize the operational template early, but make sure the contract, data-use, invention-reporting, publication, and confidentiality provisions keep pace with that standardization.
Bolster inclusion of real-world data in product development
NIH, working in conjunction with the MAHA initiative, is exploring how real-world data and causal-inference methods can improve protocol feasibility, recruitment planning, and evidence generation. The roadmap specifically points to data from electronic health records (EHR), claims, and other sources as tools that could help expedite regulatory decisions.
This is a practical opportunity, but not a shortcut around data quality. Real-world data strategies require attention to provenance, consent, privacy, interoperability, missingness, bias, and rights to link and reuse datasets. For IP teams, the data layer can become part of the asset: curated datasets, cohort definitions, causal-inference methods, and recruitment algorithms may influence both the value of a development program and the diligence questions a partner or acquirer will ask.
Advance policies to bolster rigor in clinical research
The roadmap is candid that the clinical trial enterprise has been criticized for small, underpowered studies. NIH’s answer is to tighten the front end and modernize oversight. It plans to enhance merit review through a semi-structured clinical-trial application form that should make it easier for reviewers and staff to assess significance. NIH also plans to update its 1998 Data and Safety Monitoring Policy to support high-quality data generation and participant safety while reducing unnecessary administrative burden.
A third NIH effort is a new return-of-research-results policy, intended to engage participants, incentivize participation, and build trust. That may improve retention and public confidence, but it also requires careful operational planning: consent language, privacy safeguards, communication workflows, and responsibilities for returning individual or aggregate results should be settled before trial launch, not improvised after data begin to accrue.
Expand delivery of clinical research to underserved and rural populations
NIH will also advance decentralized and hybrid trial models that bring research closer to where patients live and receive care, including rural, Tribal, and other underserved communities. Building on programs such as NIH CARE for Health, the roadmap contemplates embedding research in community-based care settings and using telehealth, AI-enabled tools, remote monitoring, and real-world data to support recruitment, consent, follow-up, and evidence generation while maintaining rigor, privacy, and participant protections.
For sponsors, this is not only an access issue; it is an evidence-quality issue. Broader trial reach can improve accrual, retention, representativeness, and early patient access. But it also requires disciplined planning around data capture, remote-device validation, chain of custody, site training, cybersecurity, and privacy. For IP and regulatory counsel, decentralized trials should be treated as part of the development architecture, not as a late operational overlay.
ARPA-H: moonshots aimed at bottlenecks
ARPA-H is the roadmap’s moonshot layer. Its programs are aimed less at one-off regulatory fixes and more at scientific and operational bottlenecks that make early development slow, expensive, and fragile.
CATALYST is focused on predictive human and computational models designed to evaluate safety and efficacy before human testing begins. The goal is to reduce reliance on animal testing where scientifically appropriate, improve prediction of toxicities that traditional models may miss, and generate evidence that can support more efficient early clinical development pathways. The roadmap also notes close coordination with FDA, which matters because these tools will only change development behavior if regulators trust the evidence they generate.
THRIVE is directed to new clinical trial and development models for advanced therapies and genetic medicines, including platform-based and umbrella trial approaches. The attraction is obvious: related therapies or disease targets could be evaluated within more flexible development structures, reducing repeated work across similar products and aligning with FDA’s interest in innovative trial designs, flexible CMC approaches, and use of prior knowledge.
ENGINE and UNICORN address the manufacturing and long-term-evidence problems that continue to challenge cell and gene therapies. The roadmap describes computational and AI-enabled tools to optimize manufacturing, reduce batch variability and failure rates, improve product quality, and better predict long-term clinical outcomes. These programs may be especially important for products where the manufacturing process is tightly bound up with the product itself.
The additional point for IP professionals is that ARPA-H’s most valuable outputs may be platform assets rather than product-specific assets: model architectures, training datasets, assay standards, manufacturing controls, quality-decision tools, and protocol logic. Sponsors participating in or building on these programs should resolve background and foreground IP, data access, government-rights obligations where federal funding is involved, publication timing, model-validation responsibilities, and trade-secret protection before those assets become embedded in an IND package or future platform program.
ONC: building the data plumbing for faster trials
The Office of National Coordinator for Health Information Technology’s (ONC’s) role is to make TrialBlazer’s clinical-research ambitions technically usable at the point of care. The roadmap’s ONC initiatives matter because many trial delays begin long before IRB approval or site contracting: clinicians do not know a relevant trial exists, EHR systems do not surface it at the right moment, and eligibility criteria live in static protocol documents that cannot be reliably queried.
Integrate clinical trial systems with EHRs
The roadmap notes that ONC-certified EHRs are now a cornerstone of the U.S. health system, with adoption by approximately 99% of hospitals and 90% of providers. It also notes that ClinicalTrials.gov contains information useful for trial identification and preliminary eligibility screening, including disease focus, recruitment status, enrollment timelines, and study locations. ONC could propose, through a future Health IT Certification regulation, that certified EHRs have the capability to integrate with the publicly available ClinicalTrials.gov API.
If finalized and adopted, this would move trial discovery closer to the clinical encounter. A clinician could identify potentially relevant trials from within the EHR during care delivery rather than relying on memory, manual registry searches, or referral networks. That will not solve eligibility screening by itself, but it could reduce one of the most basic enrollment failures: patients are willing to participate, but no one identifies the right opportunity at the right time. Sponsors should watch this closely because better EHR integration will increase the practical importance of accurate, current, and machine-readable ClinicalTrials.gov entries.
Make clinical trial protocols computable
The roadmap’s second ONC initiative is to make trial protocols computable. Today, protocols are largely unstructured documents. That makes it difficult to automatically screen patients, difficult for regulators to validate submissions, and difficult for sponsors to reuse protocol logic across systems. The roadmap points to standards initiatives that are building the foundation for digital protocols, including ICH M11/ceSHarP, CDISC’s Unified Study Definitions Model (USDM), and HL7 FHIR-based clinical study protocol efforts.
Computable protocols could eventually allow eligibility criteria, endpoints, visit schedules, data elements, and protocol logic to move across EHRs, trial-management systems, sponsor databases, and regulatory submissions without repeated manual translation. In practical terms, that means faster patient matching, fewer screening failures, easier protocol reuse, and potentially more consistent regulatory review. But it also creates new governance issues: version control, audit trails, ownership of protocol logic, liability for erroneous matching, privacy and cybersecurity, and rights to reuse computable protocol elements across programs. For IP and data teams, “protocol as data” should be treated as an asset class, not merely an administrative artifact.
Reading TrialBlazer alongside the rest of the world
This is where the multi-jurisdictional lens matters most. TrialBlazer is explicitly a reaction to regulatory competition, which means it should be read next to the systems it is chasing:
• Australia’s CTN system remains the speed benchmark for Phase 1, and a genuine option for sponsors seeking rapid first-in-human data, though counsel should weigh how Australian-generated data and any associated IP and exclusivity positions translate back into U.S. and EU strategies.
• China’s reformed pathway, including its use of investigator-initiated trials for cutting-edge modalities, offers speed but, as the roadmap itself notes, with tradeoffs in oversight and quality control, and with the well-known IP, data-integrity, and geopolitical considerations that accompany China-origin assets and licensing deals.
• The EU and other established systems are not the roadmap’s focus, but the same logic applies: where speed-to-clinic differs, value migration follows.
The strategic takeaway is not that sponsors should reflexively run first-in-human in whichever jurisdiction is fastest. It is that time-to-clinic has become a first-order variable in IP and regulatory strategy, sitting alongside patent term, data exclusivity, freedom-to-operate, publication timing, and collaboration strategy in the early planning calculus.
What practitioners should do now
This roadmap is mostly a statement of intent - pilots, draft guidances, “considering rulemaking,” roundtables, and RFIs - so the near-term value is in positioning and in shaping the final rules.
• Track the rulemakings and draft guidances. The sIRB rulemaking, the NAMs and streamlined-toxicology guidances, the CMC clarifications, substantial-evidence guidance, and master-protocol guidance are the items most likely to change real-world filing practice. Build them into client guidance updates and standard operating assumptions for IND planning.
• Use the comment channels. The public docket and roundtable series are open invitations to influence how “phase-appropriate” requirements, trial activation, participant payment, and sponsor-payment uncertainty are defined. Sponsors with platform technologies, advanced-therapy programs, or decentralized trial models should weigh in early.
• Revisit early-stage development geography. Where a program runs first-in-human now has clearer downstream consequences for value capture and IP. Make time-to-clinic an explicit input in portfolio and filing strategy, not an afterthought handled by clinical operations alone.
• Re-examine platform IP and data governance. Prior-knowledge reuse, ARPA-H model development, NIH network playbooks, and computable protocols all point in the same direction: reusable development infrastructure is becoming a strategic asset. Tighten trade-secret, ownership, publication, background-IP, foreground-IP, and data-rights provisions accordingly.
• Prepare for EHR-enabled trial matching and computable protocols. Trial discovery and eligibility screening may increasingly depend on machine-readable registry entries, standardized protocol logic, EHR interoperability, and reliable data pipelines. Regulatory, privacy, and IP teams should be involved before those tools become operational defaults.
• Watch the China-licensing dynamic. The roadmap’s central anxiety, U.S. dollars financing offshore IP and clinical records, is also a deal-structuring reality. Diligence on China-origin assets should account for where and under what standards the foundational clinical, manufacturing, data, and IP record was built.
Bottom line
Operation TrialBlazer is a speed strategy with an IP subtext. Its operational reforms, clarified IND requirements, the QRI-based Expedited-IND pilot, single-IRB review, streamlined nonclinical testing, reduced reliance on unnecessary animal studies, stronger NIH trial infrastructure, ARPA-H platform tools, EHR-enabled trial matching, and computable protocols, are aimed at clinical operations. But their deeper purpose is to keep the most valuable early asset in drug development, first-in-human data and the IP and investment that cluster around it, rooted in the United States.
Whether the reforms deliver will depend on execution, cross-agency coordination, stakeholder engagement, and whether draft guidances and pilots become durable practice. For IP and regulatory professionals, the action item is the same regardless of how the politics play out: treat time-to-clinic as a strategic IP variable, follow the rulemaking closely, and use the open comment channels while the framework is still being written.
This post was written by Lisa Mueller.